How Does Fra-1 Regulate The Invasive Properties Of Tumour Cells?
Funder
National Health and Medical Research Council
Funding Amount
$468,119.00
Summary
Most cancer deaths occur when tumours spread and destroy vital body functions. The invasion of tumour cells into surrounding tissue is a critical step during the spread of cancer. This project aims to unravel the molecular mechanisms that control the ability of tumour cells to invade into surrounding tissue and subsequently spread to other sites in the body. We expect to identify potential targets to better diagnose and treat the spread of cancer.
Analysis Of The Apoptotic And Therapeutic Effects Of Histone Deacetylase Inhibitors On Multiple Myeloma
Funder
National Health and Medical Research Council
Funding Amount
$287,321.00
Summary
Multiple myeloma (MM) is an incurable progressive cancer of plasma cells within blood. It is the second most common blood cancer and represents 2% of all cancer-related deaths. Statistics show increasing incidence and decreasing age of onset. The cause and progression of MM is poorly understood and current treatments are frequently followed by relapse. This project will assess exciting new therapies against the survival of MM cells leading to more effective treatments in the future.
Molecular Markers Of Phenotype, Therapeutic Responsiveness And Prognosis In Human Cancers.
Funder
National Health and Medical Research Council
Funding Amount
$11,762,117.00
Summary
This proposal aims to identify molecular markers that can be used to classify subtypes of particular cancers according to their prognosis and response to therapy. This will optimise selection of patients for the most appropriate treatment and lead to the development of new therapeutic strategies.
Identification Of Breast And Ovarian Tumour Suppressor Genes On Chromosome 22 By Functional Complementation
Funder
National Health and Medical Research Council
Funding Amount
$249,250.00
Summary
Cancer is fundamentally a genetic disease that arises when errors (mutations) accumulate in genes involved in regulating how and when cells grow. An important class of gene involved in this process are the tumour suppressors whose primary function is to inhibit cell growth. It is widely believed that significant improvements in the treatment and diagnosis of cancer will only be achievable once we have a detailed understanding of how these genes work. It is likely that dozens of tumour suppressor ....Cancer is fundamentally a genetic disease that arises when errors (mutations) accumulate in genes involved in regulating how and when cells grow. An important class of gene involved in this process are the tumour suppressors whose primary function is to inhibit cell growth. It is widely believed that significant improvements in the treatment and diagnosis of cancer will only be achievable once we have a detailed understanding of how these genes work. It is likely that dozens of tumour suppressor genes exist in the human genome and of these only a small proportion have been identified. The aim of this study is to identify genes on human chromosome 22 that are involved in the development of breast and ovarian cancer. Genetic evidence from many investigators, including data from our own laboratory, has indicated that multiple tumour suppressor genes are present on human chromosome 22 but as yet none have been positively identified. Part of the difficulty in identifying these genes is that cancer cells often have a lot of genetic damage and it is hard to distinguish the important changes from background genetic noise'. To circumvent this problem we are using a functional cloning approach which identifies tumour suppressor genes by their ability to inhibit the growth of cancers cells grown in culture in the laboratory. Genes that are identified in this way will be evaluated for the presence of genetic mutations in real human cancers which will give us a better idea of their true significance in tumour development. In addition to enhancing our understanding of the process tumour development this project may identify new targets for anti-cancer therapies.Read moreRead less
Biomarkers Of Phenotype, Prognosis And Response To Therapy In Pancreatic Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$105,845.00
Summary
Pancreatic cancer (PC) is the 4th leading cause of cancer deaths in our society. This research is aimed at the discovery of novel biomarkers with the ability to forecast prognosis and response to treatments in patients with PC. Ultimately, this will lead to the “individualisation” of the treatment for each patient, so that the most appropriate therapy could be given to an individual patient. This would significantly improve the overall survival and the quality of life for patients.
Australian Prostate Cancer Collaboration (APCC) Bio-Resource
Funder
National Health and Medical Research Council
Funding Amount
$2,310,000.00
Summary
The Australian Prostate Cancer Collaboration (APCC), supported by the Commonwealth Bank, Prostate Cancer Foundation of Australia and Andrology Australia, has been developing an Australia-wide network of prostate tissue banks and associated clinical databases for the past 3 years. The concept of this innovative project is to establish “nodes” or branches of the tissue bank in each State where tissues are collected and to coordinate the use of this material from a central committee or “head office ....The Australian Prostate Cancer Collaboration (APCC), supported by the Commonwealth Bank, Prostate Cancer Foundation of Australia and Andrology Australia, has been developing an Australia-wide network of prostate tissue banks and associated clinical databases for the past 3 years. The concept of this innovative project is to establish “nodes” or branches of the tissue bank in each State where tissues are collected and to coordinate the use of this material from a central committee or “head office”. A website has been established (www.apccbioresource.org.au) that is the national face of this ‘virtual’ national tissue bank and 7 State-based tissue bank consortiums are participating in this venture. The goal of this ‘virtual bank’ or network is to further enhance the national research effort by facilitating greater collaboration nationally and providing better access to, and optimal utilisation of, the clinical material available to facilitate improvements in prostate cancer management. Operational support for the nodes is critical for the success of a national Bio-Resource.Read moreRead less
The Role Of Snail Family Proteins In Stem Cells And Tumour Growth
Funder
National Health and Medical Research Council
Funding Amount
$589,175.00
Summary
This project investigates the role of a family of genes in regulating stem cells in normal tissues and cancer. This family can switch other genes off and we hypothesize that keeping these genes off is required to allow stem cells to be maintained in tissues. We combine novel studies in fruit flies and mice to examine gene function in stem cells and tumour initiation. These studies will increase our knowledge of how to manipulate stem cells and may identify new targets for tumour therapy.
Epigenetic Silencing Of Large Chromosomal Regions In Prostate Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$745,356.00
Summary
Epigenetics is a term that desribes modification of gene expression without a change to the DNA sequence through processes that involve chemical change to the DNA such as methylation. In this grant we will further characterise and understand the mechanism involved in long range epigenetic silencing and determine its prevalence in prostate cancer. This study will provide potential novel targets for prostate cancer detection, prognosis and therapy.
Regulation Of PML By E6AP: Implications For Tumour Development.
Funder
National Health and Medical Research Council
Funding Amount
$537,829.00
Summary
PML is a vital tumour suppressor, but little is known about its regulation. We established that PML levels are affected by another cellular protein E6AP. This study will define the mechanism by which E6AP influences PML. Human cancers will be screened for the involvement of these proteins, to gain new insights into cancer onset. The intended practical outcome of these studies is to aid cancer diagnosis and provide new anti-cancer drugs.